ApprovedFDA approval

Pasatru (garetosmab-grts)

Regeneron Pharmaceuticals (REGN)

Marketer take

Joins Sohonos in fibrodysplasia ossificans progressiva and was followed five weeks later by Mirum's Atebrioz, so a very small specialist community will compare three options; Pasatru's label is adults only.

Sponsor company
Regeneron Pharmaceuticals (REGN)
Indication
To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva
Therapeutic area
Rare disease
Event
FDA approval
Date
Aug 19, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move